Evox is developing therapies for diseases with well-defined genetic drivers, including Spinocerebellar Ataxia type 2 (SCA2) via ATXN2 targeting, and Huntington’s disease through MSH3 suppression, with potential relevance to other repeat expansion disorders. This evidence concerns the gene MSH3 and spinocerebellar ataxia type 2.